Switch from Ibalizumab to Lenacapavir in a Rescue Regimen for a Heavily Treatment-Experienced (HTE) Patient with Multidrug-Resistant (MDR) HIV-1 Infection
Salvatore Martini(University of Campania "Luigi Vanvitelli"), Mariantonietta Pisaturo(University of Antwerp), Adriana Raddi(Ospedale di Belcolle), Antonio Russo, Nunzia Cuomo(Federico II University Hospital), Carmine Minichini(University of Campania "Luigi Vanvitelli"), Roberta Palladino(University of Campania "Luigi Vanvitelli"), Mario Starace(Vita-Salute San Raffaele University), Lorenzo Salmoni(University of Campania "Luigi Vanvitelli")
Cited by 0
Related Papers
Anticoagulant treatment in COVID-19: a narrative review
|Journal of Thrombosis and Thrombolysis|2020|111
Multi-Criteria Decision Analysis to prioritize hospital admission of patients affected by COVID-19 in low-resource settings with hospital-bed shortage
|International Journal of Infectious Diseases|2020|75
Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity—LINA cohort)
|Hepatology International|2018|64
A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients
|Journal of Neurology|2024|49
Improvement in the aetiological diagnosis of acute hepatitis C: A diagnostic protocol based on the anti-HCV-IgM titre and IgG Avidity Index
|Journal of Clinical Virology|2009|41